Drug survival and efficacy of anti-interleukin 23 biologics in psoriasis: a comparative study on different agents-Reference-Cited by-同舟云学术

Drug survival and efficacy of anti-interleukin 23 biologics in psoriasis: a comparative study on different agents

Published:2022-11-29 Issue:4 Volume:48 Page:379-381
ISSN:0307-6938
Container-title:Clinical and Experimental Dermatology
language:en
Short-container-title:

Author:

Roccuzzo Gabriele¹,Mastorino Luca¹,Susca Sara¹,Cariti Caterina¹,Passerini Stefania G¹,Sciamarrelli Nadia¹,Borriello Silvia¹,Macagno Nicole¹,Sliquini Niccolò¹,Avallone Gianluca¹,Verrone Anna¹,Stroppiana Elena¹,Quaglino Pietro¹,Ortoncelli Michela¹,Dapavo Paolo¹,Ribero Simone¹

Affiliation:

1. Department of Medical Sciences, Section of Dermatology, University of Turin , Turin , Italy

Publisher

Oxford University Press (OUP)

Subject

Dermatology

Link

https://academic.oup.com/ced/advance-article-pdf/doi/10.1093/ced/llac098/49103487/llac098.pdf

Reference8 articles.

1. Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study;Dapavo;J Dermatol Treat,2022

2. Risankizumab shows high efficacy and maintenance in improvement of response until week 52;Mastorino;Dermatol Ther,2022

3. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study;Megna;J Dermatolog Treat,2022